This study is to determine the long-term levels of CNTF, and the clinical safety and efficacy of the NT-501 implants with the Medica Hollow Fiber Membrane (MHFM) in participants with macular telangiectasia type 2.

开始日期2025-04-01

申办/合作机构

Neurotech Pharmaceuticals, Inc.

NCT04729972 / Completed临床2期

Phase II, Multicenter, Open-label Safety Study of Bilateral NT-501 in Participants With Macular Telangiectasia Type 2

This is a multi-center, open-label, 6-month study to evaluate the safety of bilateral CNTF implants in participants with Macular Telangiectasia Type 2.

开始日期2021-08-13

申办/合作机构

Neurotech Pharmaceuticals, Inc.

[+1]

NCT04577300 / Recruiting临床2期IIT

A Randomized, Sham Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for the Treatment of Glaucoma

To determine the safety and efficacy over 24 months of dual NT-501 CNTF encapsulated cell therapy (ECT) on visual impairment related to glaucoma.

开始日期2021-05-15

申办/合作机构

Stanford University

100 项与 Revakinagene taroretcel 相关的临床结果

登录后查看更多信息

100 项与 Revakinagene taroretcel 相关的转化医学

登录后查看更多信息

100 项与 Revakinagene taroretcel 相关的专利（医药）

登录后查看更多信息

项与 Revakinagene taroretcel 相关的文献（医药）

2024-03-01·Current Opinion in Ophthalmology

Future directions of glaucoma treatment: emerging gene, neuroprotection, nanomedicine, stem cell, and vascular therapies

Review

作者: Fernandez, Elise ; Ciociola, Elizabeth C. ; Kaufmann, Mary ; Klifto, Meredith R.

Purpose of reviewThe aim of this article is to summarize current research on novel gene, stem cell, neuroprotective, nanomedicine, and vascular therapies for glaucoma.Recent findingsGene therapy using viral vectors and siRNA have been shown to reduce intraocular pressure by altering outflow and production of aqueous humor, to reduce postsurgical fibrosis with few adverse effects, and to increase retinal ganglion cell (RGC) survival in animal studies. Stem cells may treat glaucoma by replacing or stimulating proliferation of trabecular meshwork cells, thus restoring outflow facility. Stem cells can also serve a neuroprotective effect by differentiating into RGCs or preventing RGC loss via secretion of growth factors. Other developing neuroprotective glaucoma treatments which can prevent RGC death include nicotinamide, the NT-501 implant which secretes ciliary neurotrophic factor, and a Fas-L inhibitor which are now being tested in clinical trials. Recent studies on vascular therapy for glaucoma have focused on the ability of Rho Kinase inhibitors and dronabinol to increase ocular blood flow.SummaryMany novel stem cell, gene, neuroprotective, nanomedicine, and vascular therapies have shown promise in preclinical studies, but further clinical trials are needed to demonstrate safety and efficacy in human glaucomatous eyes. Although likely many years off, future glaucoma therapy may take a multifaceted approach.

2023-09-01·Ophthalmology Science

Phase I NT-501 Ciliary Neurotrophic Factor Implant Trial for Primary Open-Angle Glaucoma

Article

作者: Goldberg, Jeffrey L ; Nuñez, Mariana ; Albini, Thomas A ; Beykin, Gala ; Lam, Byron L ; Satterfield, Kellie R

PurposeTo assess the safety and efficacy of a ciliary neurotrophic factor (CNTF) intraocular implant on neuroprotection and neuroenhancement in glaucoma.DesignOpen-label, prospective, phase I clinical trial.ParticipantsA total of 11 participants were diagnosed with primary open-angle glaucoma (POAG). One eye of each patient was assigned as the study (implant) eye.MethodsThe study eye was implanted with a high-dose CNTF-secreting NT-501 implant, whereas the other eye served as a control. All patients were followed up for 18 months. Analysis was limited to descriptive statistics.Main Outcome MeasuresPrimary outcome was safety through 18 months after implantation assessed by serial eye examinations, structural and functional testing, and adverse events (AEs) recording. Parameters measured included visual acuity (VA), Humphrey visual field (HVF), pattern electroretinogram, scanning laser polarimetry with variable corneal compensation (GDx VCC), and OCT. These parameters were also used for secondary analysis of efficacy outcome.ResultsAll NT-501 implants were well tolerated with no serious AEs associated with the implant. The majority of AEs were related to the implant placement procedure and were resolved by 12 weeks after surgery. Foreign-body sensation was the most commonly reported AE and was self-limited to the postoperative period. The most common implant-related AE was pupil miosis; no patients underwent explant. Visual acuity and contrast sensitivity decreased more in fellow eyes than in study eyes (VA, -5.82 vs. -0.82 letters; and contrast sensitivity, -1.82 vs. -0.37 letters, for fellow vs. study eyes, respectively). The median HVF visual field index and mean deviation measurements worsened (decreased) in fellow eyes (-13.0%, -3.9 dB) and improved (increased) in study eyes (2.7%, 1.2 dB). Implanted eyes showed an increase in retinal nerve fiber layer thickness measured by OCT and by GDx VCC (OCT, 2.66 μm vs. 10.16 μm; and GDx VCC, 1.58 μm vs. 8.36 μm in fellow vs. study eyes, respectively).ConclusionsThe NT-501 CNTF implant was safe and well tolerated in eyes with POAG. Eyes with the implant demonstrated both structural and functional improvements suggesting biological activity, supporting the premise for a randomized phase II clinical trial of single and dual NT-501 CNTF implants in patients with POAG, which is now underway.Financial DisclosuresProprietary or commercial disclosure may be found after the references.

2021-03-01·Veterinary Ophthalmology4区 · 农林科学

Medical anti‐glaucoma therapy: Beyond the drop

4区 · 农林科学

Review

作者: Eaton, Joshua Seth ; Miller, Paul E.

AbstractBarriers to effective medical therapy are numerous and include difficulties with effective and sustained control of intraocular pressure (IOP) and adherence to prescribed anti‐glaucoma drop regimens. In an effort to circumvent these challenges, a number of new anti‐glaucoma therapies with sustained effects have emerged. Methods for sustained delivery of prostaglandin analogs are being intensely investigated and many are in human clinical trials. Intracameral devices include the following: Allergan's Durysta™ Bimatoprost SR, Envisia Therapeutics’ ENV515 travoprost implant, Glaukos’ iDose™, Ocular Therapeutix's OTX‐TIC travoprost implant, and Santen's polycaprolactone implant with PGE2‐derivative DE‐117. Other prostaglandin‐based technologies include Allergan's bimatoprost ring (placed in the conjunctival fornix), Ocular Therapeutics’ OTX‐TP intracanalicular travoprost implant, subconjunctival latanoprost in a liposomal formulation, and the PGE2 derivative PGN 9856‐isopropyl ester that is applied to the periorbital skin. Exciting breakthroughs in gene therapy include using viral vectors to correct defective genes such as MYOC or to modulate gonioimplant fibrosis, CRISPR technology to edit MYOC or to alter aquaporin to reduce aqueous humor production, and siRNA technology to silence specific genes. Stem cell technology can repopulate depleted tissues or, in the case of Neurotech's Renexus® NT‐501 intravitreal implant, serve as a living drug delivery device that continuously secretes neurotrophic factors. Other unique approaches involve nanotechnology, nasal sprays that deliver drug directly to the optic nerve and noninvasive alternating current stimulation of surviving cells in the optic nerve. Over time these modalities are likely to challenge the preeminent role that drops currently play in the medical treatment of glaucoma in animals.

项与 Revakinagene taroretcel 相关的新闻（医药）

2024-11-11

·Pharmaceutical Technology

FDA delays priority review of Neurotech’s eye cell therapy implant

Neurotech’s NT-501 implant contains allogeneic retinal pigment epithelium (RPE) cells that produce therapeutic proteins and ciliary neurotrophic factor (CNTF) for targeted and continuous treatment. Image credit: GoodStudio / Shutterstock. Neurotech Pharmaceuticals’ eye cell therapy implant has faced a setback as the US Food and Drug Administration (FDA) has extended its Prescription Drug User Fee Act (PDUFA) date. The US regulatory agency has changed the PDUFA date for the therapy’s biologics license application (BLA) for NT-501 (revakinagene taroretcel) to 18 March 2025, three months after the original date of 17 December 2024 the FDA set back in June. The agency stated that it needed the extra time to “review additional data provided by the Neurotech in response to recent requests from the FDA”. The company is seeking approval for the NT-501 implant as a treatment for macular telangiectasia type 2 (MacTel), a rare ocular neurodegenerative disease. The implant received fast track designation for this indication in December 2018. The NT-501 cell therapy implant contains allogeneic retinal pigment epithelium (RPE) cells. The implant has a semipermeable membrane that allows the therapeutic proteins like the ciliary neurotrophic factor (CNTF), produced by the RPE cells, to exit whilst protecting these cells from the host’s immune system, providing a targeted and continuous treatment. The company has previously shared that two parallel Phase III trials (protocol A, NCT03316300; protocol B, NCT03319849) of NT-501 met its primary endpoint of the rate of change in ellipsoid zone area loss, which correlates to loss of photoreceptors and sight, from baseline through 24 months. The rate of reduction of progression of disease in the treatment group in protocol A and B studies was 56.4% and 29.2%, respectively. The company also noted that the implant was safe, durable, and well tolerated in both trials. Multiple companies are developing cell and gene therapies for eye disorders . SparingVision has an adeno-associated virus-based gene therapy, SPVN20 , for improving visual acuity in patients with advanced and late-stage retinitis pigmentosa. The therapy is being evaluated in patients with stage two and three retinitis pigmentosa patients in the Phase I/II PRODYGY study (NCT05748873). Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva . Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper Cell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead. Thank you. You will receive an email shortly. Please check your inbox to download the Whitepaper. By Cytiva Thematic By downloading this Whitepaper, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

临床3期细胞疗法优先审批基因疗法快速通道

2024-11-08

·Business Wire

Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)

CUMBERLAND, R.I.--( BUSINESS WIRE )--Neurotech Pharmaceuticals, Inc., an innovator in sustained drug delivery for chronic retinal diseases, today announced that the U.S. Food and Drug Administration (FDA), has extended the Prescription Drug User Fee Act (PDUFA) goal date by three months to allow time required for the FDA to review additional data provided by the Company in response to recent requests from the FDA. The new PDUFA goal date for the biologics license application (BLA) of NT-501 (revakinagene taroretcel) as a treatment for Macular telangiectasia type 2 (MacTel) is March 18, 2025. “We are committed to providing the Agency any information needed to complete the review of the NT-501 BLA,” said Richard Small, Chief Executive Officer. “Neurotech will continue in our effort to bring this important therapy to MacTel patients.” About Macular Telangiectasia (MacTel) Macular Telangiectasia Type 2 (MacTel), or idiopathic juxtafoveal macular telangiectasia type 2, is a rare neurodegenerative disease with characteristic localized retinal degeneration and secondary alterations of the retinal vasculature. 1 MacTel typically affects both eyes and causes a gradual deterioration in central vision. About Encapsulated Cell Therapy (ECT) The ECT platform is a cell-based delivery system designed to provide long-term, sustained delivery of therapeutic proteins for the treatment of chronic retinal diseases. This versatile platform consists of a small, semi-permeable capsule containing proprietary allogeneic retinal pigment epithelium (RPE) cells genetically engineered to produce specific therapeutic proteins for targeted disease treatment. The capsule is surgically inserted into the patient’s vitreous and sutured to the sclera during an outpatient procedure. Once in place, the capsule's semi-permeable membrane allows essential nutrients to enter, while also permitting the therapeutic proteins to exit into the vitreous, providing targeted and continuous treatment. Simultaneously, the membrane protects the encapsulated RPE cells from the host's immune system, ensuring their long-term survival and functionality. About NT-501 Implant NT-501 leverages our ECT platform to deliver CNTF for the treatment of chronic retinal diseases, such as MacTel. CNTF is a potent neuroprotective protein that promotes the survival and maintenance of photoreceptors. This targeted therapy provides sustained delivery of CNTF, aiming to slow retinal degeneration and potentially improve long-term visual outcomes for patients. About Neurotech Pharmaceuticals, Inc. Neurotech Pharmaceuticals, Inc. is a private, clinical stage biotechnology company and an innovator in sustained drug delivery for chronic retinal diseases. The core platform technology, ECT, enables continuous production of therapeutic proteins to the back of the eye. For more information about us, please visit https://www.neurotechpharmaceuticals.com . 1. Charbel Issa P, Gillies MC, Chew EY, Heeren TFC, Bird AC, Peto T, Holz FG, Scholl HPN (2013) Macular Telangiectasia Type 2.

细胞疗法

2024-06-21

·药明康德

预防糖尿病的安全口服疗法；创新细胞疗法获FDA优先审评资格……

▎药明康德内容团队编辑预防糖尿病，口服疗法达到2期临床主要终点 Aphaia Pharma公司日前宣布，其用于治疗糖尿病前期的在研疗法APHD-012在2期临床试验中达到了主要终点。数据显示，与安慰剂相比，APHD-012在6周给药后在口服葡萄糖耐受测试（OGTT）异常的个体中显著改善了葡萄糖耐受，并且具有良好的安全性。在一组包含健康人、糖尿病前期和糖尿病患者的志愿者中，6周APHD-0126治疗在OGTT中将血糖水平从9.0±0.6 mmol/L降低到7.9±0.6 mmol/L（n=23，p=0.01）；接受安慰剂治疗无显著效果（从8.8±0.4 mmol/L降至8.5±0.6 mmol/L；p=0.33）。亚组分析显示，APHD-012在糖尿病前期患者中的效果更显著，将血糖水平从8.7±0.4 mmol/L降低到6.8±0.5 mmol/L；n=12，p=0.003）；在该亚组中，安慰剂无显著效果。 APHD-012是一种专有的口服葡萄糖配方，设计在小肠的特定部位释放，以恢复内源性营养感知信号通路，并刺激控制多种稳态功能的广谱肠激素的释放，包括胰高血糖素样肽1（GLP-1）、胰多糖素和氧促胰多糖素（OXM）等。创新细胞疗法获FDA优先审评资格，治疗视网膜退化疾病 Neurotech Pharmaceuticals公司日前宣布，为细胞疗法revakinagene taroretcel（NT-501）递交的生物制品许可申请（BLA）获得FDA授予的优先审评资格，用于治疗2型黄斑毛细血管扩张症（MacTel）。 Revakinagene taroretcel基于该公司独特的封装细胞疗法（encapsulated cell therapy，ECT）平台。它将表达睫状神经营养因子（CNTF）的同种异体视网膜色素上皮（RPE）细胞封装在微小的移植物中，这些移植物在植入到眼睛中后可以持续释放CNTF，从而延缓视网膜退化，潜在改善患者的长期视力。移植物具有通透性的外膜在允许营养物质进入和CNTF释放的同时，保护移植细胞不受到宿主免疫系统的攻击，确保它们的长期存活和功能。 Revakinagene taroretcel在两项3期临床试验中已经获得积极结果，显著降低了2型MacTel患者的疾病进展速度。亨廷顿病疗法2期临床结果积极 PTC Therapeutics日前分享了在研疗法PTC518治疗亨廷顿病（HD）患者的2期临床试验PIVOT-HD的中期结果。在第12个月时，接受PTC518治疗患者队列中显示出剂量依赖性突变亨廷顿蛋白（mHTT）的降低。此外，多项与HD相关的临床评估都表现出有利趋势。而且经过12个月的治疗，PTC518继续表现良好的安全性和耐受性。数据显示，在第12个月时，5 mg和10 mg剂量的PTC518分别将血液中的mHTT水平降低了22%和43%。在脑脊液中，5 mg和 10 mg剂量分别降低mHTT水平21%和43%。此外，在第12个月时，PTC518在缓解运动症状进展上表现出显著效果，根据总运动评分（TMS）评估，5 mg和10 mg剂量组的症状加重分别为2.0和1.3分，而安慰剂组为4.9分。开发潜在“first-in-class”PI3Kδ别构调节剂，新锐完成8000万欧元融资 iOnctura日前宣布完成8000万欧元的B轮融资。iOnctur正在开发一系列精准口服小分子抗癌药物。该公司已将两种候选疗法推进到中期临床开发阶段。主打在研药物roginolisib是一款PI3Kδ别构调节剂，具有独特的化学结构和结合模式。新闻稿指出，roginolisib有潜力成为首个成功靶向PI3Kδ关键癌症通路的治疗方法。此次融资将用于加速roginolisib用于治疗葡萄膜黑色素瘤（UM）的临床试验，这是一种眼部罕见癌症，目前可用的治疗方法很少。在一项1b期临床试验中，roginolisib在UM中表现出长期安全性和可喜的疗效，且在数月内持续保持临床活性。 iOnctura的第二个临床开发项目cambritaxestat是一款autotaxin抑制剂，用于治疗autotaxin过表达的高度纤维化肿瘤。目前，cambritaxestat联合化疗治疗转移性胰腺癌的1b期临床试验正在进行中。 2.75亿美元合作！潜在“best-in-class”疗法即将进入临床 Alivexis和Melodia Therapeutics今日宣布，双方已签署了一项独家许可协议，在全球范围内开发、制造和商业化Alivexis的MDI-0151，这是一种具有“best-in-class”潜力的组织蛋白酶C（cathepsin C）抑制剂。Melodia将迅速启动MDI-0151的IND申请，为针对多种由中性粒细胞过度激活引起的难治性炎症性疾病的1/2a期临床试验做准备。根据协议条款，Alivexis授予Melodia在全球范围内开发、制造和商业化MDI-0151的权利，并将从Melodia获得高达约2.75亿美元的预付款和开发及销售里程碑付款。MDI-0151抑制的组织蛋白酶C是一种负责激活在中性粒细胞破坏组织中起重要作用的蛋白酶的酶。由于抑制组织蛋白酶C对中性粒细胞的免疫功能影响较小，MDI-0151可能在有效治疗各种免疫和炎症性疾病同时，不会削弱免疫系统。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料： [1] Neurotech Receives Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a Treatment for Macular Telangiectasia Type 2 (MacTel). Retrieved June 20, 2024, from https://www.neurotechpharmaceuticals.com/receives-priority-review-for-bla-for-nt-501/ [2] iOnctura announces EUR80 million Series B financing to progress pipeline through Phase II trials. Retrieved June 20, 2024, from https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2024/06/iOnctura-Financing-PR-19-6-FINAL.pdf [3] Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients. Retrieved June 20, 2024, from https://ir.ptcbio.com/news-releases/news-release-details/interim-pivot-hd-results-demonstrate-evidence-favorable-cns [4] APHAIA PHARMA ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL EVALUATING ITS LEAD DRUG FORMULATION. Retrieved June 20, 2024, from https://aphaiapharma.com/news/aphaia-pharma-announces-positive-results-from-phase-2-trial-evaluating-its-lead-drug-formulation/ [5] Melodia Therapeutics and Alivexis Sign Exclusive License Agreement for Cathepsin C Inhibitor Program MOD-A. Retrieved June 21, 2024, from https://www.businesswire.com/news/home/20240620110656/en/Melodia-Therapeutics-and-Alivexis-Sign-Exclusive-License-Agreement-for-Cathepsin-C-Inhibitor-Program-MOD-A 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

优先审批临床2期细胞疗法临床结果ASH会议

100 项与 Revakinagene taroretcel 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
2型黄斑毛细血管扩张症	申请上市	美国	Neurotech Pharmaceuticals, Inc.	2024-06-20
视网膜毛细血管扩张	药物发现	澳大利亚	Neurotech USA, Inc.	2018-01-19
色觉障碍	药物发现	美国	Neurotech USA, Inc.	2012-07-07
全色盲1型	药物发现	美国	National Eye Institute	2012-07-01
Usher综合征	药物发现	美国	Neurotech USA, Inc.	2012-01-20
视网膜色素变性	药物发现	美国	Neurotech USA, Inc.	2007-04-16
地图样萎缩	药物发现	美国	Neurotech USA, Inc.	-
青光眼	药物发现	美国	Neurotech USA, Inc.	-
视神经疾病	药物发现	美国	Neurotech USA, Inc.	-
视神经疾病	药物发现	美国	University of Miami	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EURETINA2024	N/A	2型黄斑毛细血管扩张症	-	NT-501	醖製獵顧鏇膚鏇淵齋觸(壓鬱獵糧憲鏇遞築繭夢) = 願簾網積選獵積遞夢鬱積衊鑰膚鏇簾艱襯繭夢 (鏇膚夢醖糧壓顧衊鹹鬱, 0.05 ~ 0.10)	-	2024-09-19
				Sham treatment	醖製獵顧鏇膚鏇淵齋觸(壓鬱獵糧憲鏇遞築繭夢) = 選艱憲衊鹽餘夢遞壓顧積衊鑰膚鏇簾艱襯繭夢 (鏇膚夢醖糧壓顧衊鹹鬱, 0.14 ~ 0.19)
EURETINA2024	N/A	2型黄斑毛细血管扩张症	-	NT-501	蓋鹹憲廠鹽餘繭餘獵製(積鹽鹽餘廠鑰廠獵築製) = 鹹顧艱選餘遞築鑰淵構網鬱壓衊網壓網鏇壓選 (繭醖鹽廠鏇衊衊蓋淵襯 ) 更多	-	2024-09-19
				Revakinagene Taroretcel (Sham)	膚壓鏇襯廠廠憲夢築醖(獵憲範顧膚齋衊壓鹹簾) = 願顧鏇觸壓構觸齋鑰膚醖淵蓋觸醖築窪餘築願 (鹽鬱選廠鬱獵鹽顧繭鏇 )
EURETINA2023	N/A	2型黄斑毛细血管扩张症	-	NT-501	餘蓋淵壓艱蓋網蓋餘夢(願衊網艱壓簾襯餘壓蓋) = Non-ocular SAEs were comparable between treatment groups in NTMT-03-A (NT-501, 17.2% [10/58]; sham, 10.5% [6/57]) and NTMT-03-B (NT-501, 13.6% [8/59]; sham, 18.5% [10/54]), and none were related to treatment 選膚蓋餘襯鏇網鹹網遞 (觸網憲願獵齋衊顧艱鬱 ) 更多	-	2023-10-05
				Revakinagene Taroretcel (Sham treatment)
ARVO2023	N/A	-	-	NT-501 Implant	齋簾繭襯餘醖遞廠製鹹(鏇窪構膚鹽範餘觸鬱獵) = 願夢築廠齋艱艱衊遞鑰膚齋夢鬱構鹹鏇醖簾顧 (繭鬱鏇遞範願窪簾衊網 )	-	2023-04-23
NCT03316300 (Protocol A, Biospace) 人工标引	临床3期	2型黄斑毛细血管扩张症	115	NT-501	(鹹窪遞淵鏇繭淵餘鑰積) = 餘鏇鹽艱選齋襯鏇窪構鬱鹽糧構窪鑰夢鑰艱糧 (壓獵選觸窪窪餘鹽窪憲 )	积极	2022-11-02
				Sham Procedure	-
NCT03316300 (Protocol A, Pubmed) 人工标引	临床3期	2型黄斑毛细血管扩张症 \| 黄斑变性	-	NT-501	(鑰網範製糧窪顧壓繭鹽) = 積選膚壓夢繭願襯齋網鏇顧淵糧鏇醖獵遞鑰簾 (鹹襯襯夢鹽積獵襯鬱範, 0.19)	积极	2021-03-15
				untreated	(鑰網範製糧窪顧壓繭鹽) = 廠鏇製膚製遞夢範窪網鏇顧淵糧鏇醖獵遞鑰簾 (鹹襯襯夢鹽積獵襯鬱範, 0.11)